1
=
-
Merck & Co., Inc.
As of May 21, 2026 at 10:03 UTC
Chart
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Market Statistics
Trading Metrics
How to Buy MRK
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MRK
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesOorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.
Regeneron Pharmaceuticals' stock dropped 10.20% in premarket trading after its Phase 3 melanoma trial failed to meet its primary endpoint. While the high-dose fianlimab combination showed numerically higher progression-free survival (11.5 months vs 6.4 months), it missed statistical significance with a p-value of 0.0627. The company also announced a partnership with Telix Pharmaceuticals to develop radiopharmaceutical therapies.
Revolution Medicines' experimental pancreatic cancer drug daraxonrasib has generated significant demand from cancer centers following FDA approval of its expanded access program in May. The Phase 3 RASolute 302 trial showed the drug doubled overall survival to 13.2 months versus 6.7 months for standard chemotherapy. However, the company faces operational challenges managing the compassionate use process, and RVMD stock declined 3.47% despite the positive clinical results.
A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.
The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.
